|
|
The past several years have seen numerous advances in Alzheimer’s disease (AD) diagnosis and management. Most recently, approval of antiamyloid monoclonal antibodies has revolutionized AD management and has required that patients have amyloid burden verified prior to initiating treatment. Biomarkers, whether obtained from cerebrospinal fluid (CSF) or positron emission tomography (PET) scans, are critical to the early diagnosis of AD and its subsequent management. Plasma biomarkers are an eme...
Integritas Communications
|
CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com
Terms of Service.
Site Map
